All In Biotech

Drug Trial Radar · NCT06990867

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

740

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Oct 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Corxel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Conditions

  • Acute Ischemic Stroke

Interventions

  • JX10Drug

    JX10 is a thrombolytic agent.

  • PlaceboDrug

    Placebo is being used as the comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Proportion of participants with no or minimal symptoms (mRS score 0-1) at 90 daysTime frame: 90 days
  2. Safety: Incidence of symptomatic intracranial hemorrhage within 36 hours post-randomizationTime frame: Within 36 hours post-randomization

Locations

104 sites in 21 countries. Site status is shown where the registry gives one.

  • Corxel Investigational Site

    Long Beach, California · Recruiting

  • Corxel Investigational Site

    Los Angeles, California · Recruiting

  • Corxel Investigational Site

    Sacramento, California · Recruiting

  • Corxel Investigational Site

    Colorado Springs, Colorado · Recruiting

  • Corxel Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • Corxel Investigational Site

    Delray Beach, Florida · Recruiting

  • Corxel Investigational Site

    Chicago, Illinois · Recruiting

  • Corxel Investigational Site

    Wichita, Kansas · Recruiting

  • Corxel Investigational Site

    Baltimore, Maryland · Recruiting

  • Corxel Investigational Site

    Kalamazoo, Michigan · Recruiting

  • Corxel Investigational Site

    Traverse City, Michigan · Recruiting

  • Corxel Investigational Site

    St Louis, Missouri · Recruiting

  • Corxel Investigational Site

    Great Neck, New York · Recruiting

  • Corxel Investigational Site

    New York, New York · Recruiting

  • Corxel Investigational Site

    Columbus, Ohio · Recruiting

  • Corxel Investigational Site

    Toledo, Ohio · Recruiting

  • Corxel Investigational Site

    Tulsa, Oklahoma · Recruiting

  • Corxel Investigational Site

    Chattanooga, Tennessee · Recruiting

  • Corxel Investigational Site

    Dallas, Texas · Recruiting

  • Corxel Investigational Site

    Houston, Texas · Recruiting

  • Corxel Investigational Site

    Ghent, Belgium · Recruiting

  • Corxel Investigational Site

    Hasselt, Belgium · Recruiting

  • Corxel Investigational Site

    Blagoevgrad, Bulgaria · Recruiting

  • Corxel Investigational Site

    Burgas, Bulgaria · Recruiting

  • Corxel Investigational Site

    Pleven, Bulgaria · Recruiting

  • Corxel Investigational Site

    Plovdiv, Bulgaria · Recruiting

  • Corxel Investigational Site

    Sofia, Bulgaria · Recruiting

  • Corxel Investigational Site

    Edmonton, Canada · Recruiting

  • Corxel Investigational Site

    Kingston, Canada · Recruiting

  • Corxel Investigational Site

    Winnipeg, Canada · Recruiting

  • Corxel Investigational Site

    Baotou, China · Recruiting

  • Corxel Investigational Site

    Beijing, China · Recruiting

  • Corxel Investigational Site

    Beijing, China · Recruiting

  • Corxel Investigational Site

    Changchun, China · Recruiting

  • Corxel Investigational Site

    Guangzhou, China · Recruiting

  • Corxel Investigational Site,

    Harbin, China · Recruiting

  • Corxel Investigational Site

    Harbin, China · Recruiting

  • Corxel Investigational Site

    Kaili, China · Recruiting

  • Corxel Investigational Site

    Linfen, China · Recruiting

  • Corxel Investigational Site

    Nanyang, China · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.